A. Maiorino

Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open‐label study

M. D’Agostino, C. De Simone, F. Tassone, 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

TNF‐alpha gene polymorphisms can help to predict response to etanercept in psoriatic patients

C. De Simone, F. Perino, G. Caldarola, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Circulating endothelial cell levels in psoriatic patients and their modification after an anti‐TNF‐alpha (Etanercept) treatment

C. De Simone, E. Capoluongo, V. Coco, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy

R. Ravasio, A. Costanzo, S. Losi, 2019, Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish.

Melanoma and non-melanoma skin cancer in psoriatic patients treated with high-dose phototherapy

K. Peris, C. De Simone, F. Perino, 2016, The Journal of dermatological treatment.

Brown globules in lentigo maligna (LM): A useful dermoscopic clue.

G. Argenziano, C. Longo, A. Di Stefani, 2016, Journal of American Academy of Dermatology.

Clinical predictors of nonresponse to anti‐TNF‐α agents in psoriatic patients: A retrospective study

K. Peris, C. De Simone, F. Tassone, 2016, Dermatologic therapy.

Treatment Patterns and Pharmacoutilization in Patients Affected by Psoriasis: An Observational Study in an Italian Real-World Setting

D. Sangiorgi, E. Giacomini, V. Perrone, 2022, Drugs - Real World Outcomes.

Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy

R. Ravasio, A. Costanzo, S. Losi, 2021, Global & regional health technology assessment.

Management of recurrent cutaneous abscesses during therapy with infliximab.

C. De Simone, R. Murri, G. Caldarola, 2011, Clinical therapeutics.